Milestone Pharmaceuticals' Key Presentation at AHA 2025
Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical leader in cardiovascular medicine, is gearing up to present significant findings at the American Heart Association (AHA) Scientific Sessions 2025, an event that will take place from November 7-10 in New Orleans. This presentation promises to deliver valuable data focusing on the efficacy and safety of Etripamil, a novel treatment for patients experiencing paroxysmal supraventricular tachycardia (PSVT).
Details of the Presentation
The anticipated poster presentation is entitled ‘Combined Efficacy, Safety, and Test Dose Tolerability of Etripamil for Acute Paroxysmal Supraventricular Tachycardia (PSVT) Across Multiple Clinical Trials’. This session is scheduled for Monday, November 10, 2025, from 10:30 to 11:30 AM CST. The insights will be shared by Dr. James Ip, an esteemed Associate Professor and Director of Cardiac Pacing and Implantable Devices at Weill Cornell Medicine and New York Presbyterian Hospital. With his expertise, Dr. Ip will highlight how Etripamil has been instrumental in addressing the challenges faced by patients with this heart condition.
Understanding Paroxysmal Supraventricular Tachycardia (PSVT)
PSVT is a common form of abnormal heart rhythm that can lead to severe symptoms, including palpitations and dizziness. Milestone Pharmaceuticals recognizes the profound impact that effective treatments can have on improving the quality of life for those affected by this condition. Etripamil, an innovative self-administered medication, aims to empower patients by providing them with a reliable option to manage their episodes more effectively.
Milestone Pharmaceuticals' Vision and Efforts
At its core, Milestone Pharmaceuticals Inc. is dedicated to developing groundbreaking cardiovascular therapies. Their commitment extends to enhancing treatment options for various heart conditions, primarily through innovative solutions like Etripamil. Recently, Milestone made headlines by submitting a New Drug Application (NDA) to the U.S. Food and Drug Administration for Etripamil, signaling its potential to revolutionize the management of PSVT. This milestone underscores the company’s ongoing efforts to address unmet medical needs and improve patient outcomes.
The Future of Cardiovascular Treatment
As it continues to push the boundaries of what is possible in the realm of cardiovascular care, Milestone is not only focusing on drug development but also on patient empowerment. With initiatives that advocate for patient education and awareness, the company aims to bridge the gap between innovative treatment and patient accessibility.
Connect with Milestone Pharmaceuticals
For more information regarding Etripamil and ongoing research, Milestone Pharmaceuticals encourages interested parties to reach out to their Investor Relations team. Kevin Gardner represents the company in these matters and can be contacted via email at kgardner@lifesciadvisors.com. Milestone encourages open dialogue around their innovative approaches and the latest findings as they prepare for their vital AHA presentation.
Frequently Asked Questions
What is Etripamil?
Etripamil is a self-administered medication developed by Milestone Pharmaceuticals for the treatment of paroxysmal supraventricular tachycardia (PSVT), an abnormal heart rhythm.
When and where will the presentation occur?
The presentation will take place at the AHA Scientific Sessions 2025 from November 7-10 in New Orleans, specifically on November 10 from 10:30 – 11:30 AM CST.
Who is presenting Etripamil’s findings?
Dr. James Ip, an expert in cardiology from Weill Cornell Medicine, will present the findings.
What is the significance of this presentation?
The presentation will provide important data on the efficacy, safety, and tolerability of Etripamil, contributing to the growing body of knowledge regarding treatments for PSVT.
How can I get more information about Milestone Pharmaceuticals?
Interested parties can contact Kevin Gardner at Milestone Pharmaceuticals through his email for any inquiries related to the company and its developments.
